Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
Division of Clinical Research, Medical Mycology Research Center, Chiba Universitygrid.136304.3, Chiba, Japan.
J Clin Microbiol. 2022 Feb 16;60(2):e0201821. doi: 10.1128/JCM.02018-21. Epub 2021 Dec 8.
Aspergillus antibody testing is key for the clinical diagnosis of chronic pulmonary aspergillosis (CPA) with high sensitivity. However, false-negative results in patients with CPA might be obtained, depending on the Aspergillus species. The aim of this study was to investigate which factors are associated with false-negative results in Aspergillus precipitin tests and whether the sensitivity of precipitin tests in CPA is influenced by Aspergillus fumigatus and non- Aspergillus species. Between February 2012 and December 2020, 116 consecutive antifungal treatment-naive patients with CPA were identified and included in this retrospective chart review. Aspergillus species isolated from the respiratory tract of patients were identified by DNA sequencing. Characteristics of patients with positive and negative results for Aspergillus precipitin tests were compared. The sensitivity of the Aspergillus precipitin tests was compared between patients with A. fumigatus-associated CPA and non- Aspergillus-associated CPA. A non- Aspergillus species was the only factor significantly associated with negative Aspergillus precipitin test results in patients with CPA in the multivariate analysis (hazard ratio, 8.3; 95% confidence interval, 3.2 to 22.1; < 0.0001). The positivity of the Aspergillus precipitin test for patients with non- Aspergillus-associated CPA was lower than that for patients with A. fumigatus-associated CPA (84.8% versus 37.9%; < 0.0001). These results revealed that the presence of non- Aspergillus-associated CPA should be considered with a negative Aspergillus precipitin test; this finding may prevent diagnostic delay or misdiagnosis for CPA.
曲霉抗体检测具有较高的灵敏度,是慢性肺曲霉病(CPA)临床诊断的关键。然而,根据曲霉的种类,CPA 患者可能会出现假阴性结果。本研究旨在探讨哪些因素与曲霉沉淀试验的假阴性结果相关,以及 CPA 中沉淀试验的灵敏度是否受烟曲霉和非烟曲霉的影响。
在 2012 年 2 月至 2020 年 12 月期间,连续纳入 116 例抗真菌治疗初治的 CPA 患者进行回顾性图表审查。通过 DNA 测序鉴定患者呼吸道分离的曲霉种类。比较沉淀试验阳性和阴性结果患者的特征。比较烟曲霉相关 CPA 和非烟曲霉相关 CPA 患者沉淀试验的灵敏度。
多因素分析显示,非烟曲霉是 CPA 患者沉淀试验阴性结果的唯一显著相关因素(危险比,8.3;95%置信区间,3.2 至 22.1;<0.0001)。非烟曲霉相关 CPA 患者沉淀试验阳性率低于烟曲霉相关 CPA 患者(84.8%比 37.9%;<0.0001)。
这些结果表明,在沉淀试验阴性时应考虑到非烟曲霉相关 CPA 的存在,这一发现可能有助于避免 CPA 的诊断延迟或误诊。